About Us

D2 Biosciences is developing a dual payload ADC for cancer therapy. A trident approach differentiates us- use
of a proven technology, a second payload to target drug resistance and predictive biomarkers to identify
responder patient population. Systemic toxicities, drug resistance and lack of predictive biomarker are three
primary reasons for the wider clinical utility of ADCs in clinical oncology. More than 70% of all ADCs have
topoisomerase I (topoI) inhibitor payload, and this provides a unique opportunity for 25 years of our work to
be deployed effectively in the clinic. We have demonstrated that the deregulated kinase cascade causes rapid
topoI degradation and drug resistance. Using unique tools we have discovered first-in-class topoI stabilizers to
sensitize the tumor cells and overcome the drug resistance. D2 biosciences has also developed a clinically
validated predictive biomarker for this class of drug. Taken together, our dual payload ADC platform will have
transformative impact on therapeutic outcome in difficult to treat solid tumors.